Aprea Therapeutics, Inc. - Common Stock (APRE)

CUSIP: 03836J201

Q1 2023 13F Holders as of 31 Mar 2023

Security type / class
Equity / Common Stock
Total 13F shares
848,237
Total 13F value
$3,769,266
Holder snapshot 5 signals
Share change
+848,237
SEC-reported price per share
$4.44
Number of holders
15
Value change
+$3,769,266
Number of buys
15
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
12,212,719

Security key

03836J201

Report period

Q1 2023

Institutions

15

Top holders

10

APRE full security history Ownership snapshot Full 13F holder table Newer quarter: Q3 2025 Aprea Therapeutics, Inc. SEC filings Aprea Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of APRE - Aprea Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Christian S. Schade
Disclosed value leader
Christian S. Schade
Comparable rows
0/15
Latest evidence
31 Dec 2022
3/4/5 13F Highest disclosed value: $976,345 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Christian S. Schade has the largest disclosed position value at $976.3K.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Christian S. Schade's linked filing trail.
Disclosed position value Top 5
Christian S. Schade $976.3K
Scott M. Coiante $534K
Eyal C. Attar $211.3K
Gregory Alan Korbel $168.4K
Lars B. Abrahmsen $160.9K

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Christian S. Schade
3/4/5
Director
3/4/5
—
mixed-class rows
$976,345
312,846 shares
mixed-class rows
 — 28 Jul 2022
Scott M. Coiante
3/4/5
SVP, Chief Financial Officer
3/4/5
—
mixed-class rows
$533,970
234,265 shares
mixed-class rows
 — 28 Jul 2022
Eyal C. Attar
3/4/5
SVP, Chief Medical Officer, Director
3/4/5
—
denominator unverified
$211,254
57,392 shares
 — 03 Jun 2022
Gregory Alan Korbel
3/4/5
SVP, Chief Operating Officer
3/4/5
—
mixed-class rows
$168,445
81,462 shares
mixed-class rows
 — 28 Jul 2022
Lars B. Abrahmsen
3/4/5
SVP, Chief Scientific Officer
3/4/5
—
mixed-class rows
$160,855
143,700 shares
mixed-class rows
 — 10 Mar 2022
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$102,620
310,029 shares
 — 31 Dec 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
15
Shares
848,237
Rows available
15
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2023 vs Q2 2026 Across Filers

Q2 2026 holders
27
Q1 2023 holders
15
Holder diff
-12
Investor Q2 2026 Shares Q1 2023 Shares Share Diff Share Chg % Q2 2026 value Q1 2023 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .